The Realisation of Research Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive Biobanks: The role of UCL Business.

Slides:



Advertisements
Similar presentations
Clinical Expertise Database Sue Watson Head of MedTech Services Health Enterprise East.
Advertisements

West Midlands Academic Health Science Network July 24 th 2013.
University Contracting The University of Arizona Office of Research and Contract Analysis (ORCA)
Final Report Presentation By Mohammad Saber Sakhizada March,26 – 2009.
Towards a New R&D Strategy A blueprint for R&D in Health and Social Care Noreen Caine Deputy Director of R&D, DH NHS R&D Forum Annual Conference May 2005.
West Midlands Academic Health Science Network
Cambridge Enterprise Commercialisation of technology out of University of Cambridge Sénat Delegation 14 March 2006 Boris Bouqueniaux.
2nd Panel, Best Practices: “ IPR in Successful University-Industry Collaborations” Dr. Tamar Raz, CEO Hadasit, the Technology Transfer Company of Hadassah.
1. Introduction 2. Funding Instruments 3. Public Funding 4. Support from Banks 5. Private Equity Investment 6. Venture Capital 2.
Tony Davis CEO of Medilink WMAHSN Working With Industry and Wealth Creation.
Connecting the Technopark to the Incubator Association of University Research Parks, 2012 © Harold Strong, AURP Immediate Past President Director of Discovery.
Introduction to Enterprise Risk Management (ERM)
Intellectual Property Rights Margaret Lawlor Business Development Manager Faculty of Medical Sciences 2015 copyright©NewcastleUniversity 2015.
Creation of IP Culture in Universities & Advantages of Universities having an IP Culture Dr Duncan Matthews Queen Mary University of London.
John McCulloch PhD Venture Group Advisor MaRS Discovery District.
December 2008 MRC Data Support Services (DSS) Chris Morris 13 th February 2009 Sharing Research Data: Pioneers, Policies and Protocols The seventh cat.
CUHP Cambridge University Health Partners (CUHP) unites a world-leading University and three high- performing NHS Foundation Trusts centred on the Cambridge.
Dr Neil Bradshaw Director of Enterprise The role of IPR as seen by the academic community LES Annual Conference, Bristol, June 24, 2004.
Money Spinner YES Consultancy to Spin out Company Bruce Venning.
Starting a Company from Research at the UW James A. Severson, Ph.D. Vice Provost, Intellectual Property and Technology Transfer January 30, 2007.
Challenge Questions How good is our operational management?
Session 2(b) Management of Deposit Insurance Funds – MALAYSIA Wan Ahmad Ikram Chief Financial Officer Malaysia Deposit Insurance Corporation (MDIC) 1.
Disaster Recovery Policy & Procedures An Overview for Staff Prepared by MSM Compliance Services Pty Ltd.
ESRC: Overview and Priorities Maria Sigala. ESRC in Context ▶ Non-Departmental Public Body, established in 1965 ▶ The major public sector funder of social.
An Enterprising University Roger Ford Chair of Innovation and Technology Strategy.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
1 Presentation title - edit in the Master slide 1 Current Investment Opportunities Professor Rory Shaw, Medical Director, Healthcare UK, UKTI.
How to Kick Start a Social Enterprise Joanne O’Brien T: E:
Legal Problems for Heropreneurs: Taxation Issues James Rivett Pump Court Tax Chambers Monday 15 October 2012.
Citi REO Strategy & Community Relations September 15, 2009.
Medical Research BADRAG meeting Jan 2013 Dr H Sari-Kouzel.
The use of patents by a university spin-off. Sub-module BThe use of patents by a university spin-off 2/21 Structure of the case study University technology.
Access to Clinical Expertise Steve Bain David Powell Jemma Hughes Paula Jeffries.
Technology Transfer at Brookhaven SPAFOA MEMBERS’ MEETING May 21, 2015.
TurnAround Management & Business Advisory Services (TAM/BAS) Programme Nestor Partners.
UCC Governance Video Overview Bridie Hartnett, April,
Knowledge Exploitation Fund (KEF) Creating New Wealth for Wales.
ENTERPRISE ‘ Who to Talk to’ Expo 2015 Tipperary Enterprise Week.
PROMOTING TECHNOLOGY TO INDUSTRY Technology transfer objectives: enhance commercial value of invention promote technology to partner / investor identify.
Integrating Innovation
Dag Finne Senior Business Developer Bergen Teknologioverføring AS Presentation at NRI-Conference 2014, Day 2 Ways to finance innovators'
26 February 2009 Timothy Barnes, Executive Director, UCL Advances Cengiz Tarhan, Managing Director, UCL Business PLC Enterprise Engagement at UCL.
Intellectual Property Rights Margaret Lawlor Business Development Manager Faculty of Medical Sciences 3rd October 2013 copyright©NewcastleUniversity 2013.
TTO organization Paolo Landoni Department of Management, Economics and Industrial Engineering Politecnico di Milano
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
The Role of the Research Office Joint Research & Enterprise Office (JREO) St George’s University of London and St George’s University Hospitals NHS Foundation.
Business Development Team. Speakers Chris Mountford Business Development Executive Alexandra Cassidy Commercial Relations Executive.
Frank Larsen Birkeland Innovation AS Technology Transfer Office, University of Oslo Washington 2. December 2004.
Use of Administrative Data Seminar on Developing a Programme on Integrated Statistics in support of the Implementation of the SNA for CARICOM countries.
World Intellectual Property Organization DCPPS 1 presented by Mr. Vladimir Yossifov WIPO NATIONAL WORKSHOP ON INNOVATION SUPPORT SERVICES AND THEIR MANAGEMENT.
Intellectual Property Dr Laura Rush Business Development Manager Research Enterprise Services copyright©NewcastleUniversity 2015.
WP1: IP charter Geneva – 23rd June 2009 Contribution from CERN.
The Role of the University Enterprise Company The Materials Engineer Conference 19 April 2010 Teri Willey, Chief Executive Cambridge Enterprise Limited,
Integration of Health and Social Care Keith Darragh – Assistant Director Safeguarding, Quality and Business Strategy.
NATIONAL CONFERENCE Intellectual Property Policies for Universities and Innovation dr. sc. Vlatka Petrović Head, Technology Transfer Office Acting Head,
Policy on the Management of Intellectual Property in Technology Transfer Activities at CERN CERN/FC/5434/RA Technology Transfer Network Meeting – 10 th.
Linking the learning to the National Standards for Safer Better Healthcare Joan Heffernan Inspector Manager Regulation – Healthcare Health Information.
Industry’s Perspective on Industry-University Intellectual Property External Research Directors Network Industrial Research Institute, Inc. April 17, 2001.
University Licensing Dominique Kleyn 27 th June 2003.
Interaction Private Sector Working Group Discussion with USAID Global Partnerships January 30, 2014.
Review of Research-Related Agreements Between Academic Institutions and Other Entities. Manoja Ratnayake Lecamwasam, PhD Intellectual Property and Innovation.
ip4inno Module 4C IP Licensing Name of SpeakerVenue & Date.
Cambridge Enterprise: Services to industry and academia CamBridgeSens 6 th November 2013 Julian Peck, Technology Associate Cambridge Enterprise Limited,
“Translational research includes two areas of translation. One (T1) is the process of applying discoveries generated during research in the laboratory,
Introduction to Business (MRK 151)
Types of information systems in organizations and its characteristics
Professor Bryan Williams Chair of Medicine UCL
ECMCs – Where Do We Fit In?
Impact of Fee Reductions on Ability of Universities to Access the Patent System – Developed Country Experience Anne Lane Executive Director UCL Business.
Contracting Considerations in Research & Innovation
Presentation transcript:

The Realisation of Research Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive Biobanks: The role of UCL Business

An Introduction to UCL Business PLC  Most universities have a Technology Transfer office:  Imperial Innovations, Cambridge Enterprise, Isis Innovations (Oxford).  UCLB is a wholly owned subsidiary of UCL:  Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets.  Moorfields, GOSH, RFH and UCLH.  UCLB is a commercial entity:  Financially self-sufficient  55 Employees  Profitable  Strong Board with industry expertise  Part of UCL Enterprise

 Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets.  Four core business aspects  Service to UCL (and others)  Investment – Licensing  Investment – Company creation  Investment – Product development to market An Introduction to UCL Business PLC

 Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets.  Four core business aspects  Service to UCL (and others) MTAs  Investment – Licensing Commercial Access to Material  Investment – Company creation Abcodia Ltd  Investment – Product development to market Biobanks: the role of UCL Business PLC

Material Transfer Agreements Materials transfer agreements (MTAs) govern the transfer of one or more materials from the owner/custodian/authorised licensee to another entity who may wish to use the material for research purposes.

Why MTAs? HTA compliance “If human tissue is transferred between establishments given to minimising the likelihood of theft, damage or loss during transport. Some form of formal arrangement, for example, as part of a Material Transfer Agreements (MTA) should define how the human tissue is preserved, any potential contamination risks associated with it and who is responsible for disposal if applicable.” – Section 112, HTA Code of Practice 9 Liabilities Publication Acknowledgement Further information on human tissue transfer: Further information on MTAs: researcher/material-transfer-agreements

Improve efficiency −Avoid negotiation phase −Automate the application and approval process −Cut out paperwork and physical signatures The Realisation of Research Facilitate monitoring and management of agreements −Exportable reporting Attract interest from external organisations

 Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets.  Four core business aspects  Service to UCL (and others) MTAs  Investment – Licensing Commercial Access to Material  Investment – Company creation Abcodia Ltd  Investment – Product development to market Biobanks: the role of UCL Business PLC

Commercial Access to Material Why do industry want to access biobanks:  Biomarker discovery and validation.  Discovery\validation targets for therapeutic intervention.  Screening therapeutics toxicology\efficacy  Access to the wealth of clinical/experimental expertise at UCL and Partner Hospitals. Why should we engage with industry:  Collaborative research / commercial impact.  Income generation to maintain the biobank resource.  Income generation to supplement research.

Commercial Access to Material Important considerations:  Permissions  Grant\funder terms and conditions  Value of samples Licensing:  Fee for access  Non-exclusive license to material  Value Add

 Our remit is to support the translation and dissemination of UCL research through commercialisation of UCL’s intellectual assets.  Four core business aspects  Service to UCL (and others) MTAs  Investment – Licensing Commercial Access to Material  Investment – Company creation Abcodia Ltd  Investment – Product development to market Biobanks: the role of UCL Business PLC

Company Creation  UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)  Professors Jacobs and Menon UCL IfWH  Incorporated 2010  Licensed in IPRs and pre-existing license  Secured VC-funding alongside UCLB  Winner of four awards in December 2012  Exploitation of a unique cohort of longitudinal serum samples for biomarker discovery and validation

 Formed from one of the world’s largest cancer screening studies (UKCTOCS)  Funded by MRC, CRUK, NHS.  Collection from >200,000 female volunteers across the UK  Post-menopausal, free from disease at the start of the collection  Repeat samples collected annually from 50,000 volunteers, for up to 10 years  Total of 5 million aliquots of serum, stored sealed straws in liquid nitrogen at -176C  DNA and protein measurable  Associated Clinical Data  Detailed demographic information, including lifestyle data  Emergent disease incidence, plus family disease history  Cancer: Trachea, Bronchus and Lung, Breast, Ovarian, Colorectal, Pancreatic, Bladder and Liver  Non Cancer : Hypertension, diabetes, Angina, Rheumatoid Arthritis, Osteoarthritis, Parkinson’s, Senile dementia.  Ethics and approval  Volunteer consent and ethics approval in place for commercial use Study Overview

 Uniquely allows within-subject experimental designs  Longitudinal measures of molecular change, ahead of emergent disease  Avoids the need to seek ‘matched’ controls, enables improved measures of sensitivity  Use of the large numbers of subjects remaining disease-free to provide statistical power in cross-subject designs  Biomarker Discovery and Validation  Diagnostics, prognostics or at risk screening  Access for industry at commercial rates.  No cost for academic access. Commercial Opportunities

Any questions? Chris Williams Senior Business Manager Mars Bai Legal Affairs Executive UCL Business PLC The Network Building 97 Tottenham Court Road London W1T 4TP Tel: Web: Further information on HTA: tissue-act Further information on MTAs: researcher/material-transfer-agreements Further information on UKCTOS: ademic_research/gynaecologicalcancer/gcrc/ukct ocs Further information on Abcodia: